ReviewCurrent cardiology reports2025
Leadless Devices: the Future of Pacing.
Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Top developments in clinical cardiac electrophysiology-2025.Heart rhythm O2 · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewLeadless pacemakers (LPMs) are an established alternative to transvenous pacing systems for the treatment of bradyarrhythmias. This review outlines the evolution of LPMs, summarizes available safety and efficacy data, and highlights future development for leadless systems and the challenges that lie ahead. RECENT
findingsData from prospective cohort studies, large patient registries, and meta-analyses demonstrate high implantation success rates and fewer long-term complications with LPMs when compared to transvenous systems. Recent advances in leadless systems include dual-chamber devices capable of atrial and ventricular synchronous pacing and LPMs integrated with subcutaneous defibrillators. Future directions for leadless systems include leadless cardiac resynchronization therapy and leadless conduction system pacing. However, unresolved issues remain, including management of device end of life. LPMs are transforming cardiac pacing by reducing complications frequently observed with transvenous systems. Continued technological refinement and long-term clinical evaluation will guide broader adoption and optimize outcomes.
Indexed as
Identifiers
41457126What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.